Health Care Distributors

DAJIAWEIKANG

DAJIAWEIKANG released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 1.014 B, actual EPS CNY -1.1776

DAJIAWEIKANG released FY2025 earnings on April 27 After-Market (BJT), actual revenue CNY 5.144 B, actual EPS CNY -1.18

DAJIAWEIKANG released FY2026 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 1.384 B, actual EPS CNY 0.03

DAJIAWEIKANG FY2026 Q1 Earnings Release on April 28 After-Market (BJT)

DAJIAWEIKANG to Release FY2025 Annual Earnings on April 28 After-Market (BJT)

DAJIAWEIKANG released FY2025 Q3 earnings on October 27 After-Market BJT, actual revenue CNY 1.422 B, actual EPS CNY 0.0254

DAJIAWEIKANG released FY2025 9 Months Earnings on October 27 After-Market (BJT), with actual revenue of CNY 4.13 B and EPS of CNY 0.0377

DAJIAWEIKANG FY2025 Q3 Earnings Release on October 28 After-Market BJT

DAJIAWEIKANG released FY2025 Semi-Annual earnings on August 28 After-Market (BJT), actual revenue CNY 2.708 B, actual EPS CNY 0.004

DAJIAWEIKANG released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 1.409 B, actual EPS CNY -0.0077

DAJIAWEIKANG to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Dajia Weikang's Subsidiary Tianji Chuantang's Multiple Products Undergoing Technical Review or Application Preparation

Dajia Weikang Plans to Acquire 60.85% of Anhui Dajia Weikang for 160 Million

Dajia Weikang Plans to Acquire 60.85% Equity of Anhui Dajia Weikang Health Pharmacy

Supervisor Tangjuan of Dahajiwekang Reduces Shareholding

Supervisor Tangjuan of Dahajiwekang Reduced Shares

DJWK Executives Li Yulan Reduce Holdings by 5,000 Shares

Dajia Weikang Registers New Software Copyright and Increases R&D Investment

Dajia Weikang Executives Plan to Reduce Shares

Dajia Weikang Responds to Shareholder Numbers and Loss Reasons

000950

301126

600829

300937

000411

A-share pharmaceutical commercial stocks continue to decline, with Shuyu Pingmin dropping over 18%. HRPC, DAJIAWEIKANG, INT'L GROUP, and Hezong Medicine Easy-To-Buy Pharmaceutical all fell more than 5%, while Huaren Health, CQP, and Kaikai Industry also followed suit

Wallstreetcn

HRPC

Hezong Medicine Easy-To-Buy Pharmaceutical

INT'L GROUP

On October 31st, DAJIAWEIKANG announced that the company's board of directors recently received the resignation report from the company's deputy general manager Li Yulan. Li Yulan applied to resign from her position as deputy general manager for personal reasons. Her original term was from October 17, 2023, to October 9, 2026. According to relevant regulations, Li Yulan's resignation report will take effect from the date it is delivered to the board of directors. After her resignation, Li Yulan will no longer hold any position in the company

Zhitong

DAJIAWEIKANG: Vice President Li Yulan resigned for personal reasons

DAJIAWEIKANG released its Q3 2025 report, with operating revenue for the first three quarters amounting to 4.13 billion yuan, a year-on-year increase of 3.69%. The net profit attributable to the parent company was 5.0974 million yuan, a year-on-year decrease of 86.02%; the net profit excluding non-recurring gains and losses was 3.8818 million yuan, a year-on-year decrease of 89.02%. The basic earnings per share were 0.025 yuan

DAJIAWEIKANG released its performance for the first three quarters, with a net profit attributable to the parent company of 5.0974 million yuan, a decrease of 86.02%

DAJIAWEIKANG announced that Li Yulan plans to reduce her holdings by no more than 50,000 shares through centralized bidding from June 6, 2025, to September 5, 2025, accounting for 0.024%. She has already reduced her holdings by 5,000 shares, 15,000 shares, and 15,000 shares on June 6, July 30, and August 1, respectively, with average reduction prices of 11.01 yuan/share, 12.18 yuan/share, and 13.68 yuan/share, totaling a reduction of 35,000 shares, accounting for 0.017%. After the reduction, she holds 165,000 shares, accounting for 0.080%

DAJIAWEIKANG: Li Yulan completed a reduction of 0.017%

According to the Zhitong Finance APP, DAJIAWEIKANG released its semi-annual report for 2025, with operating revenue of 2.708 billion yuan, a year-on-year increase of 4.16%. The net profit attributable to shareholders of the listed company was 893,500 yuan, a year-on-year decrease of 97.19%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 724,400 yuan. The basic earnings per share were 0.004 yuan

DAJIAWEIKANG released its performance for the first half of the year, with a net profit attributable to the parent company of 893,500 yuan, a decrease of 97.19%

According to the Zhitong Finance APP, DAJIAWEIKANG announced that the company's director Mr. Zhong Xuesong plans to reduce his shareholding by no more than 3.5 million shares (accounting for 1.70% of the company's total share capital) through centralized bidding or block trading from September 1, 2025, to November 30, 2025

DAJIAWEIKANG director Zhong Xuesong plans to reduce his holdings by no more than 1.7%

603538

688265

300436

603987

300289

The concept of assisted reproduction has rebounded after hitting the bottom, with SMOC, Leadman, and Mailland rising over 15%. Cosunter, KDL, DAJIAWEIKANG, Zhongsheng Pharmaceutical, and Menovo followed suit

Menovo

SMOC

Cosunter

Leadman

The concept of assisted reproduction rebounds after hitting the bottom, Leadman rises over 15%

001318

002570

300966

600774

In the morning session, the baby and child, as well as assisted reproduction concepts continued to be strong, with Sunshine Dairy and Anzheng Fashion achieving three consecutive trading limits. Goto Biopharm and HSGC hit the daily limit, while DAJIAWEIKANG, Beingmate, Jinma Amusement, and Qianyuan Pharmaceutical saw significant gains

Sunshine Dairy

Beingmate

Goto Biopharm

HSGC

The infant and assisted reproduction concepts continue to be strong, with Sunshine Dairy and other stocks hitting the limit up

According to the Zhitong Finance APP, DAJIAWEIKANG announced that the company's director and senior management Chen Shanhua, supervisor Tang Juan, and senior management Li Yulan plan to collectively reduce their holdings of the company's shares by no more than 148,500 shares

DAJIAWEIKANG's certain directors and supervisors plan to collectively reduce their holdings by no more than 148,500 shares

DAJIAWEIKANG announced that the company's director and senior management Chen Shanhua plans to reduce holdings by no more than 50,000 shares, accounting for 0.024% of the company's total share capital; supervisor Tang Juan plans to reduce holdings by no more than 48,500 shares, accounting for 0.024% of the company's total share capital; senior management Li Yulan plans to reduce holdings by no more than 50,000 shares, accounting for 0.024% of the company's total share capital. The method of reduction will be through centralized bidding, with the reduction period from June 6, 2025, to September 5, 2025, and the reduction price will be determined based on market prices

DAJIAWEIKANG: Three shareholders plan to reduce their holdings by 0.024% each

DAJIAWEIKANG(301126.SZ)